Jaguar Health Launches Gelclair for Oral Mucositis in the U.S.

Jaguar Health, Inc. has announced the U.S. launch of Gelclair, an FDA-approved prescription product aimed at managing oral mucositis, a common and painful side effect of cancer treatment. This marks the company's third commercialized prescription product. Gelclair is designed to offer pain relief by coating the mucosal surfaces in the mouth without causing stinging or burning.

Oral mucositis affects a significant percentage of cancer patients, particularly those undergoing chemotherapy and radiotherapy for head and neck cancers. It can lead to detrimental impacts like difficulty eating and speaking, potentially interrupting cancer treatment. Jaguar Health's executive, Lisa Conte, emphasized the importance of this launch in supporting cancer patients' quality of life.

Napo Pharmaceuticals, part of Jaguar Health, is focusing on healthcare providers and patients with head and neck cancer, planning to present Gelclair at upcoming oncology conferences. The product aims to mitigate the onset and severity of oral mucositis, supporting continuous treatment without the need for alternative nutrition or heavy medication.